Clinical Trial Update: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) [Phase 2]

View source ↗

Summary

Phase 2 study of WU-CART-007, an allogeneic anti-CD7 CAR-T therapy, for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Lymphoma
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• WU-CART-007

Snippet

Sponsor: Wugen, Inc. | Conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Status: RECRUITING